Moderna vaccine, FDA conclusion: efficacy against COVID19 – 94.1% versus severe COVID19 – 100%
It seems that the coming days in the “covidosphere” will be marked by Moderna. Yesterday (12/15/2020), the FDA released its opinion on this company’s application for an Emergency Use Authorization (EUA) for mRNA-1273 vaccine. This is a very detailed document (54 pages, 27 tables) summarizing the protective efficacy (PE) of this vaccine and its safety, which was prepared by FDA specialists based on the primary data provided in the application (https://www.fda.gov/ media / 144434 / download). This document sets out the FDA’s position at the upcoming Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting tomorrow, whose decision, although not binding, usually determines the final FDA decision.
Judging from this document, there is no doubt that the FDA decision on the mRNA-1273 vaccine will be positive. Where such confidence? Judge for yourself.
Below is a copy of the table summarizing data on PE against COVID-19 (regardless of the severity of the disease), confirmed virologically. Cases were considered that developed from the 14th day after the second immunization.Поділитися цим: